All In Biotech

Drug Trial Radar · NCT05262270

Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)

Randomized, Placebo-Controlled Trial of Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)

Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 427 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

427

Actual

Start

Apr 18, 2023

Primary completion

Jun 27, 2025

Study completion Jul 21, 2025

Sponsor

Lead sponsor
University of Texas Southwestern Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Drug Abuse (NIDA)
First posted
Mar 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an 8-week, double-blind, randomized placebo-controlled trial of the efficacy of a combination of extended-release naltrexone (XR-NTX) and extended-release buprenorphine (XR-BUP) compared to matched placebo injections (PBO-Inj) for the treatment of cocaine use disorder (CUD).

Conditions

  • Cocaine Use Disorder

Interventions

  • Extended-Release NaltrexoneDrug

    XR-NTX (Extended-Release Naltrexone) doses of 380mg (Weeks 0, 3 and 6) via intramuscular (IM) injections in the gluteus.

  • Extended Release BuprenorphineDrug

    Extended-Release buprenorphine (XR-BUP) two doses of 300mg XR-BUP (Weeks 0, 4) via subcutaneous injections in the abdomen. Option for 100mg at Weeks 3 and 6 (if needed to alleviate side effects).

  • Placebo (PLB) Injectable matched to XR-NTXDrug

    3 doses of intramuscular injections (Week 0, 3, 6)

  • Placebo (PLB) Injectable matched to XR-BUPDrug

    2 doses of subcutaneous injections (Week 0, 4)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Cocaine-negative UDSTime frame: Week 5 up to Week 8

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • UCLA Vine Street Clinic

    Los Angeles, California

  • Center on Substance Use and Health (CSUH)

    San Francisco, California

  • Cove Behavioral Health

    Tampa, Florida

  • University of Illinois at Chicago

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Mountain Manor Treatment Center

    Baltimore, Maryland

  • Berman Center for Outcomes and Clinical Research at Hennepin Healthcare

    Minneapolis, Minnesota

  • Addictions Institute of Mount Sinai

    New York, New York

  • UTSW Medical Center, Center for Depression Research and Clinical Care

    Dallas, Texas

  • University of Texas Health San Antonio

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.